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Abstract
In recent years many efforts of researchers and clinicians were made to improve our knowledge of
cachexia syndrome. Not only cancer, but also many chronic or end-stage diseases such as AIDS,
chronic obstructive pulmonary disease (COPD), rheumatoid arthritis, tuberculosis and Crohn's
disease are associated with cachexia, a condition of abnormally low weight, weakness, and general
bodily decline which deteriorates quality of life and reduces the prognosis of the patients who suffer
from it. In the present editorial we will focus cachexia related on cancer and provide some insight
into this prognosis-limiting syndrome.
Editorial
Cancer cachexia occurs most frequently in malignancy
and is associated with more than 20% of cancer deaths
[1]. Patients with upper gastrointestinal cancer are espe-
cially likely to suffer from substantial weight loss, and
patients with pancreatic cancer have the highest frequency
of developing a cachectic syndrome. Thus the research
groups and physicians dealing with pancreatic cancer are
very interested in finding an effective treatment for
cachectic patients. But there is still little known about this
clinical issue, and our knowledge grows slowly. Much
more research and many more clinical trials are needed to
increase our understanding of the syndrome and to
develop therapeutic strategies for one of the major symp-
toms of cancer.
The word "cachexia" comes from the Greek words "kakos"
and "hexis", meaning "bad conditions" [2]. Cachexia is a
complex metabolic status with progressive weight loss
and depletion of host reserves of adipose tissue and skel-
etal muscle. Cachexia should be suspected if involuntary
weight loss of greater than five percent of premorbid
weight occurs within a six-month period [3]. Cachexia
represents the clinical consequence of a chronic, systemic
inflammatory response, with high hepatic synthesis of
acute-phase proteins resulting in depletion of essential
amino acids [4]. In contrast, in starvation only fat metab-
olism is increased while the organism tries to conserve
lean body mass [5].
In addition to metabolic changes, cachexia is often associ-
ated with anorexia. In cancer patients there can be
mechanical interference such as obstructions, as well as
treatment-related toxicity. In patients receiving chemo-
therapy or radiation, subsequent nausea, vomiting and
diarrhea can contribute to weight loss. But the lack of
nutrients alone cannot explain the metabolic changes
seen in cachexia. In clinical trials, nutritional supplemen-
tation and dietary counseling failed to increase body
weight [6]. Several appetite-stimulating drugs have been
tested in an attempt to increase the food intake of cachexia
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weight [7].
Only limited treatment options exist for patients with
clinical cancer cachexia. In one trial, corticosteroids
improved the sensation of well-being and led to increased
food intake, but this effect lasted only a few weeks [2].
Progestogens such as megestrol acetate and medroxypro-
gesterone acetate also failed to meet expectations [3,8].
Body composition analysis showed that the weight gain
resulted only from increased body fat and fluid, with no
change in lean body mass [2]. Additionally, therapy with
progestogens led to a decline in the response rate to chem-
otherapy and an increase in the frequency of thrombem-
bolic events [3,7].
Much research is currently focused on determining the
mechanism of the development of cachexia. There are two
main theories of the development of cancer cachexia.
The first theory is the pathological alteration of control
cycles. Food-intake is regulated through a complex system
of hormones and neuropeptides. Inui et al. demonstrated
that Neuropeptid Y (NPY), the most potent feeding-stim-
ulatory peptide in this cycle, is deregulated in the hypoth-
alamic orexigenic network, leading to decreased energy
intake but high metabolic demand for nutrients [9]. High
levels of leptin, a hormone secreted by adipocytes, block
the release of NPY. In cachexia the leptin feedback loop
seems to become out of control, altering the neuropepti-
dergic control cycles [9].
The second theory is based on the idea that tumor-derived
factors maintain the cachectic syndrome. Tisdale et al.
postulated a factor that was extracted from the urine of
cachectic patients and which induces protein degradation
in skeletal muscle by upregulation of the ubiquitin-pro-
teasome pathway. This proteolysis-inducing factor (PIF) is
closely related to weight loss in cachexia, and in a recent
study it was shown that PIF is produced in human colon
cancer [1,10,11].
A second factor extracted from the urine of cachectic
patients – lipid mobilizing factor (LMF) – is closely
related to weight loss and induces lipolysis in murine adi-
pocytes. A recent study showed that this lipolytic process
is mediated through the β-3 adrenoceptors. LMF produces
a significant increase in the UCPs in brown adipose tissue,
skeletal muscle and liver [12].
Mitochondrial uncoupling proteins (UCPs) 1, 2, and 3 are
involved in the control of energy metabolism through
thermogenesis in brown adipose tissue and possibly in
skeletal muscle tissue in humans. In many animal mod-
els, overexpression of UCPs (especially UCP 2) in white
adipocytes and in muscle and liver tissue was associated
with cachexia [6].
Both theories contribute to a better understanding of the
development of cancer cachexia. However, it is still uncer-
tain how they interact and whether they come into play at
the beginning or at the end stage of the disease.
Despite the controversial discussion of cachexia-inducing
mechanisms uncertainty over what causes cachexia, it is
quite clear that proinflammatory cytokines are linked to
all pathways that induce cachexia. As mentioned, cachexia
is associated with a chronic systemic inflammatory
response and the elevation of acute phase proteins. High
serum levels of IL-1, IL-6 and INF gamma are present in
many cancer patients, and the levels of these cytokines
seem to correlate with tumor progression.
These cytokines stimulate the expression of leptin and/or
mimic the hypothalamic effect of negative feedback from
leptin by disarranging the signaling pathway of NPY,
resulting in long-term inhibition of food intake. IL-1
antagonizes NPY – induced feeding in rats and disrupts
the orexigenic pathway of NPY. On the other hand, cen-
tral corticotropin-releasing factor (CRF), which is upregu-
lated by IL-1, seems to influence satiety, and is a potent
anorexigenic signal [13].
UCP expression is not only increased by LMF. Tumor
necrosis factor alpha (TNF-α) also increases the mRNA
levels of UCP2 and 3. In combination with INFγ TNF-α
activates the transcription factor NFκB that leads to reduc-
tion of Myo D, a transcription factor essential for repairing
damaged muscle tissue [14].
Although IL-6 is one of the key cytokines involved in the
development of cachexia, the definite mechanisms have
not yet been clarified. Improvements in appetite and
weight gain through decreased cytokine expression after
the application of corticosteroids or special antagonists
like IL-6 antibodies were seen over short periods, but fur-
ther investigations of the cytokine system are necessary to
elucidate the interaction between host and tumor-derived
cytokines and to determine their effect on biochemical
mechanisms.
Conclusions
Many trials have been performed in the search for a treat-
ment for cachexia, but most therapies have not fulfilled
expectations. Currently, eicosapaentanoic acid is being
tested in cachectic patients. Eicosapaentanoic acid seems
to interfere with the signaling pathway of PIF, and first
results are promising [4]. Future therapies may consist of
anticatabolic and anabolic drugs in combination with
appetite stimulants.Page 2 of 3
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Although in recent years our understanding of cachexia
has increased, we are still in the fledgling stages. The sci-
entists and clinicians dedicated to finding an effective
treatment for cachectic patients have their work cut out for
them.
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